Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 4:05 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 540694 | NSE: ANG

ANG Lifesciences India Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹84.46Undervalued by 316.06%vs CMP ₹20.30

P/E (15.0) × ROE (13.8%) × BV (₹50.00) × DY (2.00%)

Defaults: P/E=15

₹129.71Undervalued by 538.97%vs CMP ₹20.30
MoS: +84.3% (Strong)Confidence: 55/100 (Moderate)Models: All 4: Undervalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹40.9139%Under (+101.5%)
Net Asset ValueAssets₹49.9924%Under (+146.3%)
ROCE CapitalReturns₹457.8320%Under (+2155.3%)
Revenue MultipleRevenue₹68.7418%Under (+238.6%)
Consensus (4 models)₹129.71100%Undervalued
Key Drivers: EPS CAGR -51.6% drags value — could be higher if earnings stabilize. | Wide model spread (₹41–₹458) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -51.6% · Defaults: P/E=15

*Investments are subject to market risks

Investment Snapshot

37
ANG Lifesciences India Ltd scores 37/100 (Weak)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health41/100 · Moderate
ROCE 3.5% WeakROE 13.8% GoodD/E 0.91 ModerateInterest Coverage 0.0x RiskyProfitable 2/5 years Inconsistent
Smart Money50/100 · Moderate
Promoter holding at 70.6% Stable
Earnings Quality40/100 · Moderate
OPM contracting (12% → 3%) Declining
Quarterly Momentum25/100 · Weak
Revenue (4Q): -19% YoY DecliningOPM: -11.3% (down 3.0% YoY) Margin pressure
Industry Rank30/100 · Weak
ROCE 3.5% vs industry 16.4% Below peers3Y sales CAGR: -36% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

ANG Lifesciences India Ltd Investor Signals

Computed from valuation, cash flow, balance sheet, ownership and quarterly trend data already available in this stock page.

Value Trap Score
60/100
Moderate
Derived from: Cheapness + weak quality + weak cash support
Current data: P/E 0.0 vs Ind 53.8 | ROCE 3.5% | ROE 13.8% | CFO/NP N/A
Balance Sheet Stress
30/100
Comfortable
Derived from: Leverage + debt servicing + liquidity + debt trend
Current data: D/E 0.91x | IntCov 0.0x | Current 1.16x | Borrow/Reserve 1.50x
Cash Flow Reliability
86/100
Strong
Derived from: Cash backing of earnings + working capital pressure
Current data: CFO ₹0 Cr | NP ₹-10 Cr | CFO/NP N/A
Ownership Accumulation
0
Neutral
Derived from: FII + DII + promoter direction, adjusted by crowding
Current data: FII N/A | DII N/A | Prom 0.00 pp
Business Momentum
-100
Early weakness
Derived from: Latest quarter sales + profit + OPM change
Current data: Q Sales -29.5% | Q NP -430.0% | Q OPM -19.9 pp
Derived FieldValueHow it is derived
Valuation Gap %+539.0%((Fair Value - CMP) / CMP) × 100
Borrowings / Reserves1.50xLatest borrowings divided by latest reserves
CFO / Net ProfitN/ALatest operating cash flow divided by latest net profit
FII ChangeN/ALatest FII% minus previous FII%
DII ChangeN/ALatest DII% minus previous DII%
Promoter Change0.00 ppLatest promoter% minus previous promoter%
Shareholder Count Change-189Latest shareholder count minus previous count
Quarterly Sales Change-29.5%Latest quarter sales vs previous quarter sales
Quarterly Profit Change-430.0%Latest quarter net profit vs previous quarter net profit
Quarterly OPM Change-19.9 ppLatest quarter OPM minus previous quarter OPM

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 4:05 am

Market Cap 26.5 Cr.
Current Price 20.3
Intrinsic Value₹129.71
High / Low 39.7/17.6
Stock P/E
Book Value 50.0
Dividend Yield0.00 %
ROCE3.54 %
ROE13.8 %
Face Value 10.0
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for ANG Lifesciences India Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Lactose (India) Ltd 106 Cr. 84.2 137/76.021.9 49.60.00 %12.9 %9.69 % 10.0
MPS Pharmaa Ltd 3.15 Cr. 1.65 3.17/1.57 0.330.00 %9.79 %59.0 % 10.0
Gujarat Themis Biosyn Ltd 2,692 Cr. 247 479/22256.3 24.30.27 %27.3 %21.7 % 1.00
Gujarat Terce Laboratories Ltd 25.3 Cr. 32.5 68.4/29.0 10.10.00 %41.4 %14.6 % 10.0
Gujarat Inject (Kerala) Ltd 120 Cr. 82.1 82.1/17.0481 6.930.00 %13.5 %11.0 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of ANG Lifesciences India Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 45.1731.8850.6129.5817.1034.0816.1832.1623.9117.6724.5325.9718.30
Expenses 43.0343.4844.9428.2618.8230.2318.1129.7025.8918.0322.6723.7520.37
Operating Profit 2.14-11.605.671.32-1.723.85-1.932.46-1.98-0.361.862.22-2.07
OPM % 4.74%-36.39%11.20%4.46%-10.06%11.30%-11.93%7.65%-8.28%-2.04%7.58%8.55%-11.31%
Other Income 0.329.200.340.33-0.09-1.491.360.36-0.030.750.170.210.16
Interest 2.841.111.941.961.993.441.671.871.712.051.611.591.61
Depreciation 1.922.821.941.972.021.831.511.621.841.301.451.451.45
Profit before tax -2.30-6.332.13-2.28-5.82-2.91-3.75-0.67-5.56-2.96-1.03-0.61-4.97
Tax % -30.43%-20.54%25.35%-10.09%-20.96%23.71%-26.13%61.19%-17.99%-34.46%-23.30%29.51%-14.89%
Net Profit -1.60-5.031.60-2.05-4.59-3.60-2.77-1.07-4.57-1.94-0.79-0.80-4.24
EPS in Rs -1.23-3.851.23-1.57-3.52-2.76-2.12-0.82-3.50-1.49-0.60-0.61-3.25

Last Updated: March 3, 2026, 12:25 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 7:46 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 34.5036.8454.9266.9375.13121.27126.08154.24348.52206.82131.3089.7386.47
Expenses 29.6133.7250.1960.4367.83109.63113.65138.91282.98195.15121.7590.7584.82
Operating Profit 4.893.124.736.507.3011.6412.4315.3365.5411.679.55-1.021.65
OPM % 14.17%8.47%8.61%9.71%9.72%9.60%9.86%9.94%18.81%5.64%7.27%-1.14%1.91%
Other Income 0.120.090.210.250.690.230.420.750.959.84-0.891.991.29
Interest 1.511.661.661.771.852.643.223.988.3110.929.777.646.86
Depreciation 3.050.951.061.171.191.121.232.245.128.527.756.275.65
Profit before tax 0.450.602.223.814.958.118.409.8653.062.07-8.86-12.94-9.57
Tax % 55.56%31.67%25.23%25.98%24.65%30.33%27.50%26.47%25.18%131.88%-2.48%-20.02%
Net Profit 0.190.401.652.823.725.656.107.2539.71-0.66-8.65-10.34-7.77
EPS in Rs 0.210.431.793.072.864.354.695.5830.55-0.51-6.62-7.92-5.95
Dividend Payout % 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%2.61%0.00%0.00%0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)110.53%312.50%70.91%31.91%51.88%7.96%18.85%447.72%-101.66%-1210.61%-19.54%
Change in YoY Net Profit Growth (%)0.00%201.97%-241.59%-38.99%19.97%-43.92%10.89%428.87%-549.39%-1108.94%1191.07%

ANG Lifesciences India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:9%
5 Years:-7%
3 Years:-36%
TTM:1%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:%
TTM:28%
Stock Price CAGR
10 Years:%
5 Years:6%
3 Years:-45%
1 Year:-48%
Return on Equity
10 Years:12%
5 Years:9%
3 Years:-8%
Last Year:-14%

Last Updated: September 5, 2025, 2:16 pm

Balance Sheet

Last Updated: December 10, 2025, 3:48 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 3.683.683.683.685.185.185.185.1810.3713.0613.0613.0613.06
Reserves -0.97-0.571.093.8117.9923.5829.3736.1773.1172.4864.0153.7552.20
Borrowings 11.0310.1511.7714.0117.4221.9020.8342.4060.9955.5659.3670.5878.12
Other Liabilities 11.4412.5918.9525.3427.5730.2438.6958.49124.21111.4081.0071.2880.68
Total Liabilities 25.1825.8535.4946.8468.1680.9094.07142.24268.68252.50217.43208.67224.06
Fixed Assets 9.048.789.028.909.4720.6020.9421.8982.3278.6853.3552.6349.79
CWIP 0.000.000.000.0711.570.160.230.400.000.000.000.000.00
Investments 0.020.020.020.020.020.020.020.023.523.523.523.523.52
Other Assets 16.1217.0526.4537.8547.1060.1272.88119.93182.84170.30160.56152.52170.75
Total Assets 25.1825.8535.4946.8468.1680.9094.07142.24268.68252.50217.43208.67224.06

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 3.583.131.862.730.887.464.83-11.1827.3926.01-13.13-2.29
Cash from Investing Activity + -2.14-2.32-2.92-2.56-13.40-0.77-1.66-7.79-42.50-9.3520.02-1.63
Cash from Financing Activity + -1.43-0.891.63-0.2913.10-3.80-3.9518.8115.29-16.75-7.003.92
Net Cash Flow 0.02-0.080.56-0.120.572.89-0.77-0.160.17-0.08-0.12-0.01
Free Cash Flow 2.912.430.551.61-12.386.623.19-15.25-11.9615.585.93-6.41
CFO/OP 75%103%48%54%26%84%60%-69%43%252%3%-186%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-6.14-7.03-7.04-7.51-10.12-10.26-8.40-27.074.55-43.89-49.81-71.60

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 79.6762.22108.86139.39156.19125.66133.34139.10103.67137.85192.56264.24
Inventory Days 83.9984.1446.8144.6253.4127.1841.0367.6246.2992.90143.34227.95
Days Payable 129.49129.88133.28163.44153.9690.63105.80158.84105.16153.93243.56333.86
Cash Conversion Cycle 34.1716.4822.3920.5855.6462.2168.5647.8844.8076.8392.34158.34
Working Capital Days 28.2518.7310.2314.4048.2939.7052.6047.1422.0527.8874.9771.80
ROCE %13.65%16.74%26.04%29.34%21.90%23.56%21.92%19.90%53.78%8.51%1.78%-3.54%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 70.60%70.60%70.60%70.60%70.60%70.60%70.60%70.60%70.60%70.60%70.60%70.60%
Public 29.40%29.38%29.41%29.39%29.39%29.39%29.39%29.39%29.39%29.40%29.40%29.41%
No. of Shareholders 7,1637,3057,0556,9186,8686,6316,4686,5176,5086,4006,2736,084

Shareholding Pattern Chart

No. of Shareholders

ANG Lifesciences India Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22
FaceValue 10.0010.0010.0010.00
Basic EPS (Rs.) -9.42-7.650.3639.39
Diluted EPS (Rs.) -9.42-7.650.3639.09
Cash EPS (Rs.) -4.33-1.366.9644.56
Book Value[Excl.RevalReserv]/Share (Rs.) 48.9958.4166.0280.81
Book Value[Incl.RevalReserv]/Share (Rs.) 48.9958.4166.0280.81
Revenue From Operations / Share (Rs.) 71.10111.89168.39341.77
PBDIT / Share (Rs.) -0.187.9218.2765.87
PBIT / Share (Rs.) -5.371.5111.1160.20
PBT / Share (Rs.) -12.03-8.202.0151.61
Net Profit / Share (Rs.) -9.51-7.77-0.2038.89
NP After MI And SOA / Share (Rs.) -9.51-7.77-0.2038.89
PBDIT Margin (%) -0.267.0710.8419.27
PBIT Margin (%) -7.541.346.5917.61
PBT Margin (%) -16.91-7.331.1915.10
Net Profit Margin (%) -13.36-6.94-0.1111.37
NP After MI And SOA Margin (%) -13.36-6.94-0.1111.37
Return on Networth / Equity (%) -19.40-13.29-0.3048.12
Return on Capital Employeed (%) -8.132.0112.3550.02
Return On Assets (%) -5.40-4.18-0.0913.85
Long Term Debt / Equity (X) 0.290.180.230.25
Total Debt / Equity (X) 1.260.900.810.91
Asset Turnover Ratio (%) 0.390.550.770.00
Current Ratio (X) 1.151.241.151.16
Quick Ratio (X) 0.770.900.850.93
Inventory Turnover Ratio (X) 1.822.143.650.00
Dividend Payout Ratio (NP) (%) 0.000.000.002.57
Dividend Payout Ratio (CP) (%) 0.000.000.002.24
Earning Retention Ratio (%) 0.000.000.0097.43
Cash Earning Retention Ratio (%) 0.000.000.0097.76
Interest Coverage Ratio (X) -0.020.942.017.67
Interest Coverage Ratio (Post Tax) (X) -0.420.230.975.53
Enterprise Value (Cr.) 106.47122.38163.11313.54
EV / Net Operating Revenue (X) 1.150.830.740.88
EV / EBITDA (X) -429.3011.836.844.59
MarketCap / Net Operating Revenue (X) 0.310.400.450.68
Retention Ratios (%) 0.000.000.0097.42
Price / BV (X) 0.460.771.152.90
Price / Net Operating Revenue (X) 0.310.400.450.68
EarningsYield -0.41-0.170.000.16

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

ANG Lifesciences India Ltd. is a Public Limited Listed company incorporated on 14/06/2006 and has its registered office in the State of Punjab, India. Company's Corporate Identification Number(CIN) is L24230PB2006PLC030341 and registration number is 030341. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 89.91 Cr. and Equity Capital is Rs. 13.06 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsDarbara Complex, Amritsar Punjab 143001Contact not found
Management
NamePosition Held
Mr. Rajesh GuptaManaging Director
Mrs. Saruchi GuptaWhole Time Director
Mr. Rohit MittalNon Executive Director
Mrs. ChetnaIndependent Director
Mr. Harvinder SinghIndependent Director
Mr. Sukhpal SinghIndependent Director

FAQ

What is the intrinsic value of ANG Lifesciences India Ltd and is it undervalued?

As of 04 April 2026, ANG Lifesciences India Ltd's intrinsic value is ₹129.71, which is 538.97% higher than the current market price of ₹20.30, suggesting the stock is undervalued. This is calculated using the PE ratio method factoring in ROE (13.8 %), book value (₹50.0), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of ANG Lifesciences India Ltd?

ANG Lifesciences India Ltd is trading at ₹20.30 as of 04 April 2026, with a FY2026-2027 high of ₹39.7 and low of ₹17.6. The stock is currently near its 52-week low. Market cap stands at ₹26.5 Cr..

How does ANG Lifesciences India Ltd's P/E ratio compare to its industry?

ANG Lifesciences India Ltd has a P/E ratio of , which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is ANG Lifesciences India Ltd financially healthy?

Key indicators for ANG Lifesciences India Ltd: ROCE of 3.54 % is on the lower side compared to the industry average of 16.35%. Dividend yield is 0.00 %.

Is ANG Lifesciences India Ltd profitable and how is the profit trend?

ANG Lifesciences India Ltd reported a net profit of ₹-10 Cr in Mar 2025 on revenue of ₹90 Cr. Compared to ₹40 Cr in Mar 2022, the net profit shows a declining trend.

Does ANG Lifesciences India Ltd pay dividends?

ANG Lifesciences India Ltd has a dividend yield of 0.00 % at the current price of ₹20.30. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in ANG Lifesciences India Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports